Kimberly Bolin

Cooley advised Oyster Point Pharma, a top ophthalmology-focused biopharmaceutical company, on its definitive agreement to be acquired by global healthcare company Viatris. Partners Mika Reiner Mayer, Brandon Fenn, Div Gupta and Ian Nussbaum led the Cooley team advising Oyster Point Pharma.

Cooley has worked with Myovant Sciences since 2017 to develop and prosecute its owned and licensed patent portfolios and in intellectual property diligence leading up to Myovant’s acquisition by biopharmaceutical company, Sumitovant Biopharma. The total transaction value was $1.7 billion, with a total company value of $2.9 billion. Myovant aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy.

"Myovant's two products, ORGOVYX® and MYFEMBREE® have substantial potential. We believe the combination of Sumitovant and Myovant will strengthen Myovant's product capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women's health," said Hiroshi Nomura, CEO of Sumitomo Pharma. "

Cooley advised Vera Therapeutics on its $86 million follow-on offering of 55,742,026 shares of Class A common stock at a price to the public of $15.00 per share. Vera is a late-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunological diseases. Jodie Bourdet, Brett White and Alexa Ekman led the Cooley team.

Cooley advised Neurocrine Biosciences on its strategic partnership agreement with Takeda to develop and commercialize potential therapies in Takeda’s early- to mid-stage pipeline for psychiatric disorders. The partnership will enhance Neurocrine’s growing pipeline of treatments and strengthen the company’s position as a leading neuroscience-focused biopharmaceutical company.

Neurocrine will develop and commercialize all pipeline compounds included in the collaboration. Under the terms of the agreement, Neurocrine will pay Takeda $120 million in upfront cash and up to $495 million in development milestones, $1.4 billion in commercial milestones and double-digit royalties on net sales.

Cooley advised Vaxcyte on its $287.5 million initial public offering of 17,968,750 shares of common stock, including full exercise of the underwriters’ option to purchase additional shares. Vaxcyte, whose securities now trade on the Nasdaq Global Market under the symbol “PCVX”, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. Partners Rob Phillips, Charlie Kim and Carlton Fleming led the Cooley team.